India has validated its first indigenous Human Papillomavirus (HPV) test, a move designed to lower the cost of cervical cancer screening and expand access in rural regions. Developed by Goa-based Molbio Diagnostics, the Truenat HPV-HR Plus test meets international quality standards, according to a collaborative study involving the All India Institute of Medical Sciences (AIIMS), the Indian Council of Medical Research (ICMR), and the World Health Organization’s International Agency for Research on Cancer (IARC).
Why is indigenous HPV testing critical for India?
Cervical cancer remains one of the most common cancers among Indian women, yet screening rates have historically lagged due to the high cost of imported diagnostic tools. According to Molbio Diagnostics, the current dependence on international tests often limits availability in smaller healthcare facilities. By localizing production, the Truenat HPV-HR Plus test provides a cost-effective, molecular diagnostic alternative that functions in diverse clinical settings. This shift aims to transition cervical cancer screening from a specialized urban service to a routine, community-level public health intervention.
HPV is the primary driver of cervical cancer. Because early-stage infections often present no symptoms, regular molecular screening is the only reliable method to detect high-risk HPV types before they evolve into malignant cell changes.
How does the new test compare to international standards?
The validation process confirmed that the Truenat HPV-HR Plus test performs at a level comparable to globally accepted screening tools. Researchers from AIIMS and ICMR conducted the evaluation to ensure the technology meets the rigorous quality benchmarks required by the IARC. Unlike traditional screening methods that may require centralized laboratory infrastructure, this indigenous test utilizes advanced molecular technology capable of being deployed in decentralized settings. This technical parity allows public health programs to replace more expensive, imported reagents with a locally manufactured equivalent without compromising patient outcomes.
What are the future trends for cervical cancer elimination?
The integration of indigenous testing is expected to dovetail with India’s expanding HPV vaccination efforts. According to Sriram Natarajan, CEO of Molbio Diagnostics, the move to democratize access to high-quality diagnostics is a necessary step toward the national goal of cervical cancer elimination. Future trends suggest a hybrid approach: combining widespread primary vaccination with targeted, low-cost molecular screening to identify high-risk patients who may have missed initial immunization windows or require clinical monitoring.
Pro Tip: Staying proactive with health screenings
Do not wait for symptoms to appear. Since HPV-related cell changes often occur silently, consult your primary care provider about the appropriate age to begin routine cervical cancer screening based on the latest national health guidelines.
Frequently Asked Questions
- What is the primary benefit of the Truenat HPV-HR Plus test?
It offers a more affordable, locally produced alternative to expensive imported tests, making screening more accessible for women in underserved and rural areas. - Who validated this test?
The validation was a collaborative effort between the All India Institute of Medical Sciences (AIIMS), the Indian Council of Medical Research (ICMR), and the WHO’s International Agency for Research on Cancer (IARC). - Can this test detect all types of HPV?
The test is designed to detect several high-risk HPV types that are responsible for the vast majority of cervical cancer cases.
Are you interested in learning more about public health innovations in India? Subscribe to our newsletter for updates on the latest medical breakthroughs or explore our Health & Science archive for more in-depth reporting.
